Additional file 1 of Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Additional file 1: Table S1. Details of antibodies used for multiple immunohistochemistry. Table S2. The clinical, pathological, and molecular characteristics of groups with higher or lower CLDN18 expression in TCGA cohorts. Table S3. The clinical, pathological, and molecular characteristics of CLDN18.2 positive or negative gastric cancer patients receiving immunotherapy. Table S4. The expression proportion of cell markers in CLDN18.2 positive and negative tumor tissues. Table S5. The effective score of cell markers in CLDN18.2 positive and negative tumor tissues. Table S6. The effective percent of cell markers in CLDN18.2 positive and negative tumor tissues. Table S7. The expression proportion of cell markers in CLDN18.2 positive and negative normal tissues. Table S8. The effective score of cell markers in CLDN18.2 positive and negative normal tissues. Table S9. The effective percent of cell markers in CLDN18.2 positive and negative normal tissues.